The Performance of Digital Technologies for Measuring Tuberculosis Medication Adherence: A Systematic Review

4		
5	Miranda Zary ¹ , Mona	a Salaheldin Mohamed ¹ , Cedric Kafie ¹ , Chimweta Ian Chilala ² , Shruti Bahukudumbi ³ ,
6	Nicola Foster ² , Gene	vieve Gore ⁴ , Katherine Fielding ² , Ramnath Subbaraman ^{3,5} , and Kevin Schwartzman ¹
7		
8		l Tuberculosis Centre; Research Institute of the McGill University Health Centre,
9	Montréal, Canada	
10		School of Hygiene and Tropical Medicine, London, UK
11	•	lic Health and Community Medicine, Tufts University School of Medicine, Boston,
12	USA	
13 14	⁴ Schulich Library of F Canada	Physical Sciences, Life Sciences, and Engineering; McGill University, Montréal,
15		hic Medicine and Infectious Diseases, Tufts Medical Center, Boston, USA
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29	Word count (withou	it abstract): 4 590
30		
31	Correspondence:	Dr. Kevin Schwartzman
32	·	Centre for Outcomes Research and Evaluation
33		Research Institute of the McGill University Health Centre
34		5252 boulevard de Maisonneuve Ouest, Room 3D.63
35		Montreal, Quebec H4A 3S5
36		CANADA
37		Email <u>kevin.schwartzman@mcgill.ca</u>

38 ABSTRACT (296 words)

39 Introduction: Digital adherence technologies (DATs), such as phone-based technologies, and digital

40 pillboxes, can provide more person-centric approaches to support tuberculosis (TB) medication

41 adherence. We synthesized evidence addressing the performance of DATs for measuring tuberculosis

42 medication adherence.

43 **Methods:** We conducted a systematic review (PROSPERO - CRD42022313526) which identified relevant

44 published literature from January 2000 through April 2023 in five databases, and pertinent preprints.

45 Studies reporting quantitative data on the performance of DATs for measuring adherence to

46 medications for TB disease or infection, against a reference standard, with at least 20 participants using

47 the DAT were included. Study characteristics and performance outcomes (e.g., sensitivity, specificity,

48 positive and negative predictive values) were extracted. Article quality was assessed using the QUADAS-

49 2 tool for diagnostic accuracy studies.

50 **Results:** Of 5692 studies initially identified by our systematic search, 13 met our inclusion criteria. These

51 studies addressed the performance of medication sleeves with phone calls [branded as "99DDOTS";

52 N=4], digital pillboxes [N=5], ingestible sensors [N=2], artificial intelligence-based video observed

53 therapy [N=1], and multifunctional mobile applications [N=1]. All but one involved persons with TB

54 disease. For medication sleeves with phone calls, compared to urine analysis, reported sensitivity and

55 specificity was 70-94% and 0-61%, respectively. For digital pillboxes, compared to pill count, reported

56 sensitivity and specificity was 25-99% and 69-100%, respectively. For ingestible sensors, the sensitivity of

57 dose detection was ≥95% in comparison to directly observed ingestion. Participant selection was the

58 most frequent potential source of bias across articles.

59 Conclusion: Limited available data suggest suboptimal and variable performance of DATs for dose
 60 monitoring, with significant evidence gaps, notably in real-world programmatic settings. Future research

- 61 should aim to improve understanding of the relationships of specific technologies, settings, user 62 characteristics, and user engagement with DAT performance, and should measure and report 63 performance in a more standardized manner. 64 **Key words:** digital adherence technology, systematic review, accuracy, tuberculosis, performance, 65 treatment observation, medication adherence 66 67 68 69 70 71 72 73 **KEY MESSAGES** 74 What is already known on this topic: Several cohort studies have suggested that digital adherence 75 technologies (DATs) can both underestimate and overestimate medication ingestion among persons 76 treated for tuberculosis. No previous review has synthesized available evidence in this regard. 77 What this study adds: Reports of DAT (medication sleeves with phone calls, digital pillboxes) 78 implementation in real-world treatment settings consistently indicate suboptimal performance for 79 measuring medication adherence. However, available evidence is limited in scope and quality. 80 How this study might affect research, practice, or policy: Suboptimal dose reporting from DATs 81 potentially compromises their effectiveness, and program efficiency. Future clinical practice will be 82 strengthened by rigorous technology evaluations that reflect more consistent use of reference 83 standards, and clearer benchmarks for medication adherence.
 - 84 **INTRODUCTION** (511 words)

85	Tuberculosis (TB) disease requires treatment with medication regimens involving varying pill
86	burdens lasting at least 4 months. Adherence to these treatment regimens—which involve daily
87	medication intake—is crucial, as non-adherence can lead to treatment failure, relapse, development of
88	drug resistance, ongoing TB transmission, and death.(1,2) Treatment for TB infection is between 1 and 9
89	months. Adherence to treatment for TB infection is essential to reduce the risk of developing TB disease
90	but is often difficult to achieve in routine care, particularly since treated persons are asymptomatic.(3,4)
91	Directly observed therapy (DOT) has been recommended for TB treatment support.(5) DOT involves
92	healthcare workers, or community workers, watching up to 100% of prescribed medication doses.(6)
93	However, DOT is logistically challenging, expensive, potentially intrusive, raises ethical concerns, and can
94	have limited or varying effectiveness for improving treatment outcomes.(6–8)
95	Digital adherence technologies (DATs) have been increasingly studied and used in routine care
96	as an alternative or adjunctive approach for supporting TB treatment. DATs include mobile
97	communication and other innovations that can remind people with TB to take their medication, digitally
98	observe doses taken, compile dosing histories, triage people who may be at higher risk for unfavorable
99	treatment outcomes, and enable differentiated (i.e., intensified or individualized) care.(2) DATs include
100	a range of technologies that may facilitate more person-centered approaches for monitoring adherence,
101	potentially improving treatment outcomes.(2)
102	For example, one of the most widely used DATs, branded as 99DOTS, involves wrapping a paper
103	sleeve over a medication blister pack. Dispensation of a medication dose then reveals a hidden phone
104	number. By calling this number, the person with TB can report dose ingestion, creating a digital dosing
105	history that allows early identification by healthcare providers of people who may be nonadherent.(9–
106	12) However, people with TB may call the phone number on the medication sleeve without taking their
107	doses (i.e., over-reporting adherence) or take medication doses without calling (i.e., under-reporting
108	adherence), which may hinder the ability to identify people experiencing nonadherence. Other DATs

109 that have been used in routine care by TB programs (13,14) — such as two-way short messaging service 110 (SMS), digital pillboxes, or video-supported therapy—similarly involve an SMS response, pillbox opening. 111 or remote visualization of dosing by video, respectively, serving as a proxy for a treatment dose taken. 112 All may face challenges related to over-reporting or under-reporting of adherence. 113 An initial systematic review examining DATs for TB treatment support was published in 2018. 114 However, since 2018—particularly with the COVID-19 pandemic—interest in and experience with these 115 technologies have expanded substantially.(15) While other reviews have been published subsequently 116 (2,16,17), none has examined the performance of DATs for measuring TB medication adherence, which 117 is crucial for healthcare providers to identify people with TB who may be experiencing nonadherence, so 118 they can be given intensified or individualized support. If they do not yield accurate assessments of 119 adherence, any resulting actionable information is of questionable value, resulting in limited public 120 health impact.(2) The present systematic review synthesizes evidence on the performance of digital 121 adherence technologies for measuring TB medication adherence, among persons treated for 122 tuberculosis disease and infection. 123 **METHODS** (1,178 words) 124 **Design.** Our systematic review protocol was registered in PROSPERO, the International 125 Prospective Register of Systematic Reviews (CRD42022313526).(18) This review follows the Preferred 126 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 127 Search and screening strategy. The search for relevant literature was conducted on April 28th, 128 2023 (updated from April 14, 2022) in MEDLINE/Ovid, Embase, CENTRAL, CINAHL, and Web of Science 129 Core Collection, Europe PMC preprints (including MedRxiv) and clinicaltrials.gov from January 1, 2000, to 130 April 28, 2023. Key search concepts included TB (disease or infection), digital technologies (such as

131 mobile phone, smartphone, video observation, digital pillboxes, and text messaging), and accuracy (such

132 as sensitivity, specificity, and area under the curve). The complete search strategy can be found in Table 133 S1 of the supplemental appendix. The database searches were conducted by a health librarian (GG). 134 Separately, we hand-searched the Union World Conference on Lung Health for relevant abstracts on 135 DATs and performance from 2004 to 2022 inclusively. There were no language restrictions. 136 Inclusion/Exclusion Criteria. Studies were included if they reported a quantitative outcome 137 addressing the performance of DATs for measuring TB medication adherence (i.e., any of sensitivity, 138 specificity, positive predictive value [PPV], negative predictive value [NPV], area under the receiver 139 operating characteristic curve [AUC], likelihood ratio, accuracy, or agreement). These are defined below 140 (Table 1). Articles were included if the number of participants using the DAT was at least 20, and the 141 study design included the comparison of adherence reports generated by a DAT with a reference 142 standard such as urine drug metabolite testing, pill count, direct observation of medication ingestion, or 143 other such information. DAT interventions included but were not limited to smartphone-based 144 technologies such as phone-based dosing records, SMS or video-supported treatment, digital pillboxes, 145 and ingestible sensors. We defined a DAT as an intervention with a digital component (which could be 146 part of a multi-component intervention) with the intention to measure and promote treatment 147 adherence and/or reduce missed visits and/or reduce losses to follow-up. Examples of DATs included 148 and excluded with this definition can be found in Table S2. 149 We included studies of persons treated for TB disease or infection, including subgroups such as 150 people with drug-resistant TB and people with human immunodeficiency virus (HIV). Eligible study 151 designs included all observational studies except case-control studies.(19) We excluded reports if they 152 did not, in fact, involve a DAT (Table S2), or if they were reviews, abstracts (other than from the Union 153 World Conference on Lung Health), editorials, commentaries, news articles, or study protocols. Relevant 154 grey literature (such as ministry reports, technical papers, and preprints) was accepted if it met the

eligibility criteria. A complete list of the outcomes, population, intervention, and control groups of

- 156 interest, and all inclusion/exclusion criteria can be found in Table S3.
- 157 Study Selection. After de-duplication using EndNote (Version 20.2.1 – Clarivate, London UK), 158 five reviewers (M.Z., M.S., C.C., S.B., C.K., and N.F.) independently screened all titles and abstracts for 159 their relevance to DATs for TB treatment support, supported by Rayyan.ai (Rayyan, Cambridge 160 USA).(20,21) Potentially relevant studies underwent independent full-text review by the same 161 reviewers, for eligibility according to the inclusion criteria above. Each screening stage was conducted in 162 duplicate, by two reviewers blinded to each other's assessment, with conflicts resolved by a senior 163 investigator (K.S., R.S., or K.F.). All references from and citations of each included publication were also 164 screened for inclusion using Google Scholar (Alphabet, Mountain View USA).(22) 165 Data extraction. For each included study, data were extracted into a pre-specified Excel 166 (Microsoft, Redmond USA) template by two independent reviewers (M.Z. and M.S., or C.K.) in parallel, 167 and subsequently compared for any discrepancies. Conflicts were resolved by consensus and discussion 168 with a third reviewer (K.S.) when necessary. Extracted data included study characteristics e.g., study 169 design, study setting (i.e., geographic location; inpatient or outpatient), participant characteristics, DAT 170 used, reference standard used, the approaches to classifying adherence for both the DAT and reference 171 standard (e.g., time frame and frequency of adherence assessment), and any important gaps noted by 172 the reviewers. For each study, we extracted all reported performance parameters e.g., true positives 173 (TP), true negatives (TN), false positives (FP), false negatives (FN), sensitivity, specificity, PPV, NPV, 174 accuracy, and AUC. 175 Performance parameter definitions. The performance of digital technologies for measuring TB

176 medication adherence can include an assessment of the technical performance or functioning of the 177 DAT, or the performance of the DAT for detecting human behaviour. Technical performance is assessed 178 in controlled conditions to determine whether the designated hardware or software of the DAT can

- 179 adequately detect doses known to be taken. The performance of a DAT for detecting human behaviour
- 180 is assessed in real-world conditions to determine its ability to detect a person's adherence to their
- 181 medication during their treatment course. In either condition, DAT performance can be assessed per
- 182 person or per medication dose. Table 1 contains the definitions of the performance parameters used in
- 183 this review by the unit of assessment: dose vs. person.

184 Table 1: Definitions of parameters used to describe the performance of DATs for measuring

- 185 **tuberculosis medication adherence.** Parameters are defined against a reference standard and by unit of
- 186 assessment.

Performance		
Parameter	Definition – Dose	Definition - Person
Sensitivity	The percentage of doses that were classified as taken by the DAT, among those that were taken by the	The percentage of participants who were classified as adherent by the DAT, among those who were adherent by the reference
	reference standard.	standard.
Specificity	The percentage of doses that were classified as not taken by the DAT, among those that were not taken by the reference standard.	The percentage of participants who were classified as nonadherent by the DAT, among those who were non-adherent by the reference standard.
Positive predictive value	Likelihood of a dose being taken by the reference standard among those classified as taken by the DAT.	Likelihood of a participant being adherent by the reference standard among those classified as being adherent by the DAT.
Negative predictive value	Likelihood of a dose not being taken by the reference standard among those classified as not being taken by the DAT.	Likelihood of a participant being non- adherent by the reference standard among those classified as being non-adherent by the DAT.
Accuracy	The percentage of doses that were classified as taken or not taken by both the DAT and the reference standard.	The percentage of participants who were classified as adherent or non-adherent by both the DAT and the reference standard.

187 **Data synthesis**. The extracted data were summarized in tabular form. Pre-specified subgroup

188 analyses were performed where appropriate, addressing specific DATs, TB disease vs. infection, and

189 groups at risk of unfavorable outcomes. Sensitivity and specificity estimates were displayed according to

- 190 DAT type in forest plots created using RevMan (Version 5.4 Cochrane, London UK).(23) We calculated
- 191 pertinent performance parameters that were not directly reported when these could be derived from
- 192 the underlying data. For parameters that were reported without binomial 95% confidence intervals (CI),

they were calculated, when possible, using the Clopper-Pearson Exact Method in R (Version 4.1.2 – GNU
Project).(24) This method was also used for articles that had repeated observations per individual, and
therefore does not account for within-individual clustering.

196 Publication bias was assessed qualitatively using Deek's test for diagnostic accuracy studies. (25) 197 We created a funnel plot of the association between the diagnostic odds ratio (DOR) and the effective 198 sample size (ESS) of each study. (25) Quantitative assessment for publication bias using the associated 199 regression test of asymmetry could not be performed, given the small number of included studies. 200 Quality assessment. The included articles were assessed for risk of bias and applicability 201 concerns using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool for primary 202 diagnostic accuracy studies. (26) This tool addresses participant selection, the performance of the index 203 test, the performance of the reference test, and the flow and timing of the tests. For each feature, three 204 scores could be used: low, unclear, or high. Two reviewers (M.Z. and M.S., or C.K.) independently 205 assessed each study for quality. Any conflicts were resolved by consensus and discussion with a third 206 reviewer (K.S.) when necessary. Quality assessment results are displayed in graphic and summary format 207 using RevMan (Version 5.4 – Cochrane, London UK).(23) 208 **GRADE assessment**. Finally, we rated the robustness of evidence using the Grading of

210 and strategies.(27) The GRADEpro Guideline Development Tool (McMaster University, Canada &

Recommendations, Assessment, Development, and Evaluation (GRADE) approach for diagnostic tests

211 Evidence Price, EU) was used for recommendations.(28) The risk of bias and indirectness was assessed

212 using the relevant elements of the QUADAS-2 checklist. Inconsistency and imprecision were assessed

213 based on outcome variability and confidence interval ranges across articles.

Patient and public involvement: Patients and the public were not specifically involved in thedesign, conduct, reporting, or dissemination plans of our research.

216

209

217 **RESULTS (1,775 words)**

Study selection. Figure 1 illustrates the PRISMA 2020 flow chart, beginning with the records identified by our search. After de-duplication, there were 5692 records identified, of which 5290 titles and abstracts were not relevant to TB and DATs. Of the remaining 402 reports which underwent fulltext review, nine met our inclusion criteria. Four additional reports were identified by hand-searching, for a total of 13 included reports.

223 **Overview of studies.** Of the 13 reports included, 4 involved medication sleeves with phone calls, 224 5 involved digital pillboxes, 2 involved ingestible sensors, and 1 each involved a mobile application and 225 an artificial intelligence (AI)-based technology for viewing videos of medication ingestion (known as 226 video observed therapy [VOT]). The study characteristics of the included articles can be found in Table 227 2. Ingestible sensors, VOT (AI result), and the mobile application were assessed for their technical 228 performance under controlled conditions, while medication sleeves with phone calls and digital 229 pillboxes were assessed under real-world conditions for their ability to detect adherence during TB 230 treatment. Detailed descriptions of the DATs and reference standards used for performance assessment 231 for all articles can be found in Table S4. Briefly, included articles used either isoniazid (INH) urine 232 metabolite tests, rifampicin (RIF) urine colour tests, pill counts, DOT, or healthcare provider-based 233 adherence reports to assess the performance of the DAT (Table 2). 12 articles reported on persons 234 treated for TB disease, while one considered the performance of a digital pillbox in persons treated for 235 TB infection. Two studies compared pill counts and urine drug tests with the digital pillbox as their 236 reference standard; we back-calculated performance parameters for the pillbox compared with pill 237 counts and urine tests using the primary data they reported (Table 2). One study investigating digital 238 pillboxes (Huan et al. 2012) was translated from Simplified Chinese to English using Google Translate 239 (Alphabet, Mountain View USA).(29)

Table 2: Characteristics of included studies assessing the performance DATs for measuring TB medication adherence.

			Participants				Interv	ention	Reference Test			
Study ID	Country	Participants ⁺⁺	Age (years)	N ^{¥¥}	HIV%	DAT	Duration	Adherence classification	Test	Frequency	Adherence classification	
Browne et al. 2019 (30)	United States ^{****}	DS TB disease	Mean: 43 SD: 17	77	NR	Ingestible sensors	2-3 weeks	1 detected dose	DOT	9x/person	1 dose ingested**	
Belknap et al. 2013 (31)	United States ^{****}	TB disease [¥]	Median: 44 Range: 22-79	30	10%	Ingestible sensors	2-3 weeks (10 visits)	1 detected dose	DOT	10x/person	1 dose ingested**	
Scott et al. 2023 (32)	China*** South Africa*** Spain**** USA****	TB infection	Median: 36 IQR: 27-49	665	1%	Digital pillboxes	3 months	≥ 11/12 doses recorded	Pill count	1x/person	≤1 dose remaining	
Bionghi et al. 2018§ (33)	South Africa***	MDR TB disease	Median: 42 IQR: 33.5-54	21	100%	Digital pillboxes	3 weeks	1 dose recorded	Pill count	3x/person	1 dose missing**	
Huan et al. 2012 (34)	China***	DS TB disease	Mean: 46 SD: 17	319	NR	Digital pillboxes	1-6 months	1 dose recorded in prior 24h	RIF urine colour test	1x/person	Red colour change	
van den Boogaard et al. 2011 (35)	Tanzania**	PTB and EPTB disease	Mean: 41 SD: 14	37	44%	Digital pillboxes ^{##}	6 months	100% or \geq 95% of doses recorded	Pill count INH urine test RIF urine colour test	12x/person 4x/person 4x/person	0 or <u><</u> 5% doses remaining Purple/blue colour change ^ Orange urine colour	
Ruslami et al. 2008 (36)	Indonesia**	PTB disease	Median: 32 Range: 16-84	30	NR	Digital pillboxes##	4 weeks	100% of doses recorded ⁺	Pill count	2x/person	0 doses remaining	
Subbaraman et al. 2021 ^{§§} (12)	India**	DS PTB and EPTB disease	Median: 35 IQR: 25-45	608	47%	Medication sleeves with phone calls	1-6 months	Adherence: 2 or 3 reported doses over the 2 days prior to the urine test and the day of the test Nonadherence: 0 or 1 reported doses over the 2 days prior to urine test and the day of the test	INH urine test	1x/person	Purple/blue or green colour change^	
Thomas et al. 2020 (9)	India**	DS PTB and EPTB disease	Median: 35 Range: 18-83	597	48%	Medication sleeves with phone calls	1-6 months	Adherence: 1 dose reported in the prior 6h to 48h Nonadherence: No dose reported in the prior 72h	INH urine test	1x/person	Purple/blue or green colour change^	
Efo et al. 2021 (10)	Tanzania**	DS TB disease	Range: 25-44	197	NR	Medication sleeves with phone calls	6 months	Adherence: 1 dose reported in the prior 48h Nonadherence: No dose reported in the prior 48h	INH urine test	1x/person	Purple/blue or green colour change^	
Alacapa et al. 2020† (11)	Philippines**	NR	NR	103	NR	Medication sleeves with phone calls	~3 months	Adherence: Dose reported in the prior 48h ⁺ Nonadherence: No dose reported in the prior 48h	INH urine test	1x/person	Purple/blue or green colour change^	
Sekandi et al. 2023 (37)	Uganda*	DS TB disease	Mean: 31 Range: 19-50	51	28%	Other: VOT (AI result)	N/A [#]	1 detected dose	VOT (Provider result)	10x/person	Research team identifies ingestion in VOT ⁺⁺	
Goodwin et al. 2022† (38)	Argentina***	DS TB disease	NR	NR	NR	Other: Mobile App (Software result)	N/A [#]	1 detected dose	Mobile App (Provider result)	NR	Treatment supporter/ research staff detects colour change in photo of INH Urine Test. ⁺⁺	

*low income country **lower middle-income country, ***upper middle-income country, ****high-income country

Al artificial intelligence, DOT directly observed therapy, DS drug-sensitive, DR drug-resistant, EPTB extra-pulmonary tuberculosis, INH isoniazid, IQR interquartile range, MDR multidrug-resistant, N number of participants, N/A not applicable. NR not reported. PTR pulmonary tuberculosis, BIF rifampicin, SD standard deviation, VOT video observed therapy.

N/A not applicable, NR not reported, PTB pulmonary tuberculosis, RIF rifampicin, SD standard deviation, VOT video observed therapy § Inpatient cohort

§§ Same cohort as Thomas et al. 2020 (9)

⁺ Abstract from the World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union).

++ If not specified, resistance/susceptibility details or TB type were not indicated.

¥ Potentially INH-resistant TB in some clients.

¥¥ N indicates the number of participants analyzed as part of DAT performance. Participant characteristics may be different among this specific group but were not reported in the text.

Not applicable due to batch submitted videos or photos being used to assess performance of the AI or software

Digital pillbox was used as the reference standard of the published study. Performance outcomes of the pillbox were calculated from originally published values on sensitivity, specificity, PPV, and NPV.

+ Assumed based on study information.

++ Study considered number of total medication doses across participants rather than adherence per participant's treatment cycle.

^Colour change indicates the time of last medication ingestion: Purple/blue (<24 hours ago), Green (24-48 hours ago), Yellow (>48 to 72 hours ago)

255	Assessment of adherence by the reference standard was conducted anywhere from once to
256	twelve times over participants' treatment and the duration of DAT use ranged from two weeks to six
257	months (Table 2). For two studies, authors were contacted with requests to add missing data, but they
258	did not reply. Six of the full articles reported some but not all applicable performance parameters
259	(sensitivity, specificity, PPV, NPV, accuracy; Table S5). While two studies estimated area under the
260	receiver operating characteristic (ROC) curve (Table S5), none provided ROC curves, likelihood ratios, or
261	estimated agreement. When possible, we calculated missing performance parameters from the data
262	provided (Table S5). A meta-analysis pooling performance estimates was not conducted given the small
263	number and marked heterogeneity of the studies retrieved. Only one (30) of five studies
264	(30,31,33,37,38) that analyzed repeated observations of individuals accounted for clustering in their
265	primary analysis. Summary ROC curves to demonstrate joint sensitivity and specificity were not created
266	due to the small number of studies per DAT.
267	Performance of DATs under controlled conditions.
268	Ingestible sensors. Two reports from the US addressed the performance of ingestible sensors for
269	measuring TB medication adherence in controlled conditions (Table 2).(30,31) This involved determining
270	if an on-body wearable sensor could detect the ingestible sensor placed on the medication, following its
271	ingestion which was directly observed. The percentage of doses that were correctly classified as taken
272	by the sensor's technology (sensitivity) was at least 95% across studies (Figure 2a, Table S6). Only

273 sensitivity could be estimated from these studies.

Other DATs. Two reports assessed other DATs for their ability to measure TB medication adherence under controlled conditions. In one, a deep convolutional neural network (DCNN) was used to determine whether a participant had ingested medication in a video submitted as part of a VOT intervention.(37) The performance of the artificial intelligence algorithm was compared to the research team's interpretation of the same submitted video and assessed using 5-fold cross validation, for five

types of convolutional neural networks to extract features of the videos. The best performing
convolutional neural network had a mean sensitivity of 95% (standard deviation, SD 2.6) but a specificity
of 55% (SD 6.5) (Table S6).

282 In the other report., a mobile application involved the participant's uploading a photo of their

283 INH urine test, and associated software then analyzed the images to determine whether or not they

indicated the presence of INH metabolites.(38) The output from this reader software was compared to

treatment supporter and research staff interpretation of the same urine test images. The sensitivity was

286 81% and 86% when compared to the treatment supporter and research staff interpretations,

respectively, while the percentage of doses correctly classified by the technology as not taken

288 (specificity) was 95% and 91% (Table S6).

289 Performance of DATs under real-world conditions.

290 *Medication sleeves with phone calls ["99DOTS"]*. Three studies investigated the performance of

291 medication sleeves with phone calls for measuring TB medication adherence, compared with

unannounced INH urine tests either in the clinic or at a home visit (Table 2). They generally classified

adherence as any dose reported within 48 hours before the urine test and nonadherence as no reported

dose within the previous 48 or 72 hours before the urine test. (9–11) All studies investigating this DAT

were conducted in lower middle-income countries. The sensitivity of participants' dose reports (patient-

reported doses) for detecting adherence ranged from 70% to 94%, while the specificity of participants'

dose reports for detecting nonadherence ranged from 0% to 61% (Figure 2b).

Two articles on medication sleeves with phone calls, using data from the same cohort, showed that sensitivity and specificity vary depending on the approach used to classify DAT adherence. For example, when "nonadherence" was defined as a person with TB not reporting any medication dose during the 72 hours prior to INH urine testing (9), the specificity was lower than when "nonadherence"

302 was defined as a person reporting less than either two or three medication doses in the 72 hours prior

303 to the home visit (Table 3).(12)

- 304 Table 3 Performance of medication sleeves with phone calls and digital pillboxes under real-world conditions against a reference standard. Digital pillboxes
- 305 were assessed for persons with tuberculosis disease and tuberculosis infection. If not reported, values and binomial confidence intervals were calculated from 306 other reported performance data (sensitivity, specificity, PPV, NPV, or number of TP, FP, FN, and TN).
- 307

	DAT Adherence	Reference						Sensitivity	Specificity	PPV	NPV	Accuracy
Study ID	classification	Standard	N	TP	FP	FN	TN	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)
			Me	edicatio	n slee	ves with	n phon	e calls ["99DOTS")			
Subbaraman et al.	2 or 3 reported	INH urine test	608	330	20	211	47	61% (57-65%)	70% (58-81%)	94% (91-96%)	18% (14-23%)	62% (58-66%)
2021 [§] (12)	doses in 72h prior		608 ⁺	482	45	59	22	89% (86-91%)	33% (22-45%)	91% (89-94%)	27% (18-38%)	83% (80-86%)
Efo et al. 2021 (10)	1 reported dose in prior 48h	INH urine test	197	138	7	41	11	77% (70-83%)	61% (36-83%)	95% (90-98%)	21% (12-34%)	76% (69-81%)
Thomas et al. 2020	1 reported dose in	INH urine test	597	368	28	157	44	70% (66-74%)	61% (48-72%)	93% (91-95%)	21% (18-25%)	69% (65-72%)
(9)	prior 6-48h		597 ⁺	446	44	79	28	85% (81-88%)	39% (28-52%)	91% (90-93%)	26% (20-33%)	79% (76-82%)
			287**	155	17	83	32	65% (59-71%)	66% (51-79%)	90% (86-93%)	28% (23-34%)	65% (59-71%)
			310 [¥]	213	11	75	11	74% (68-79%)	48% (26-70%)	95% (93-97%)	12% (7-18%)	72% (67-77%)
Alacapa et al. 2020 ^{§§} (11)	1 reported dose in prior 48h	INH urine test	103	95	2	6	0	94% (88-98%)	0% (0-84%)	98% (93-100%)	0% (0-46%)	92% (85-97%)
						Digital I	oillbox	es				
TB Disease						<u> </u>						
Bionghi et al. 2018 ^{¥¥} (33)	1 dose recorded	Pill count	21+ (489)	480	0	6	3	99% (97-100%)	100% (29-100%)	100% (99-100%)	33% (7-70%)	99% (97-100%)
Huan et al. 2012 ^{§§} (34)	1 dose recorded in prior 24h	RIF urine colour test	319	208	5	1	105	100% (97-100%)	95% (90-99%)	98% (95-99%)	99% (95-100%)	98% (96-99%)
van den Boogaard	<u>></u> 95% doses	Pill count	37	19	11	5	2	79% (58-93%)	15% (2-45%)	63% (44-80%)	29% (4-71%)	57% (39-73%)
et al. 2011 [#] (35)	recorded	INH urine test	37	18	12	4	3	82% (60-95%)	20% (4-48%)	60% (41-77%)	43% (10-82%)	57% (39-73%)
		RIF urine colour test	37	8	22	1	6	89% (52-100%)	21% (8-41%)	27% (12-46%)	86% (42-100%)	38% (22-55%)
	100% doses	Pill count	37	6	4	18	9	25% (10-47%)	69% (39-91%)	60% (26-88%)	33% (17-54%)	41% (25-58%)
	recorded	INH urine test	37	4	6	18	9	18% (5-40%)	60% (32-84%)	40% (12-74%)	33% (17-54%)	35% (20-53%)
		RIF urine colour test	37	2	8	7	20	22% (3-60%)	71% (51-87%)	20% (3-56%)	74% (54-89%)	59% (42-75%)
Ruslami et al. 2008 [#] (36)	100% doses recorded ^{##}	Pill count	30	15	2	5	8	75% (51-91%)	80% (44-97%)	88% (64-99%)	62% (32-86%)	77% (58-90%)
TB Infection												
Scott et al. 2023	<u>></u> 11/12 doses	Pill count	665 (Total)	497	0	40	128	93% (90-95%)	100% (97-100%)	100% (99-100%)	76% (69-82%)	94% (92-96%)
(32)	recorded		513 (USA)	395	0	17	101	96% (93-98%)	100% (96-100%)	100% (99-100%)	86% (78-91%)	97% (95-98%)
			57 (SA)	25	0	21	11	54% (39-69%)	100% (72-100%)	100% (86-100%)	34% (19-53%)	63% (49-76%)
			65 (Spain)	50	0	2	13	96% (87-100%)	100% (75-100%)	100% (93-100%)	87% (60-98%)	97% (89-100%)
						0	3	· · · ·	· · · ·	, ,	· · · · ·	100% (88-100%)
			30 (China)	27	0	0	3	100% (87-100%)	100% (29-100%)	100% (87-100%)	100% (29-100%)	100% (88-1

308 Cl confidence interval, DAT digital adherence technology, FN false negatives, FP false positives, INH isoniazid, N number of participants, NPV negative predictive value, PPV positive predictive value, 309

RIF rifampicin, SA South Africa, TN true negatives, TP true positives, USA United States of America

§ Same cohort as Thomas et al. 2020

310 311 312 §§ Abstract from the World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union)

+ Patient and provider reported doses (Patient-reported doses relies only on calls made by the participant. For patient and provider reported doses, if no call is made after 24h, healthcare workers

313 are supposed to contact the participant and report whether these doses were taken based on verbal report)

314 ++ Subpopulation of people with HIV within this cohort study.

315 ¥ Subpopulation of people without HIV in within this cohort study.

- ¥¥ Inpatient cohort
- # The digital pillbox was used as the original reference standard. Number of true positives, false positives, false negatives, and true negatives were back-calculated from the article's primary data on
- pill count or urinalysis sensitivity and specificity, and number of events.
- 316 317 318 319 320 ## Assumed based on study information
- + 489 total doses, shown in parentheses, were assessed for performance across 21 participants.

The same authors also examined dose verification added by providers, who telephoned persons who had not phoned in their doses on a given day. When provider-reported doses were added, the sensitivity of combined patient-and provider dose reports for detecting adherence increased from 70% [95% CI 66-74%] to 85% [95% CI 81-88%], but specificity for detecting nonadherence decreased from 61% [95% CI 48-72%] to 39% [95% CI 28-52%] (Table 3).(9) Estimated overall accuracy ranged from 69-92% (Table 3). Nonetheless, the negative predictive value, or likelihood of a participant being non-adherent by the urine test among those classified as being

328 non-adherent by the DAT, was consistently low (range 0-26%). In other words, non-reporting of a dose

329 by a person with TB often did not mean that they had in fact missed it—and instead often signaled

330 limited ongoing engagement with the technology.

Digital pillboxes. The five studies reporting on digital pillboxes used varying methods and were conducted in countries with differing income levels (Table 2). Two used the digital pillbox as their reference standard against multiple index tests, so we back-calculated performance estimates from their reported values (Table S5).(35,36) One assessed performance in an inpatient cohort (33), while one focused on TB infection (32). Four reports included pill counts conducted at clinic visits as at least one of their reference standards (32,33,35,36), while one used unannounced urine color testing for rifampin at home visits (34) (Table 2).

When compared against pill count for those with TB disease, three studies reported digital pillbox sensitivities for overall perfect adherence ranging from 25% to 99%, while specificity for detecting nonadherence was higher, ranging from 69% to 100% (Figure 2c).(33,35,36) The report which only used urine color testing for rifampin estimated the sensitivity and specificity of digital pillboxes for dose detection within 24h as 100% (95% CI 97-100%) and 95% (90-99%), respectively (Table 3).(34) In one article, when compared against pill count among persons treated for TB infection, digital pillboxes

were very sensitive for adherence (93% [95% CI 90-95%]) and specific for non-adherence (100% [97100%]) and generally remained so in subgroup analyses involving the various study sites (Table 3).(32)
For digital pillboxes, overall accuracy estimates ranged from 35%-100% (Table 3). As with the
medication sleeves, negative predictive values were often poor, meaning that doses not reported by
pillbox opening were not necessarily missed.

Subgroups and special populations. In an inpatient cohort of 21 individuals with both HIV and drug-resistant TB, digital pillboxes had high sensitivity and specificity (>99%) (Table 3).(33) In another study investigating medication sleeves with phone calls, a subgroup analysis of people with HIV treated for TB disease found that specificity was higher (66% [95% CI 51-79%]) among people with HIV (i.e., more nonadherence was correctly detected) than among people without HIV (48% [26-70%]) (Table 3).(9) Several other studies included persons living with HIV among their participants, but did not report results separately for this group (Table 2).(31,35) No report addressed persons younger than 18.

356 Quality Assessment. The risk of bias was high or unclear in at least two categories for all but one 357 of the reports assessed. (Figure S1a). Two reports could not be assessed for quality as the limited 358 description of their methods precluded formal assessment of bias. (11,38) Participant selection was a 359 frequent source of potential bias since participants were rarely randomly sampled; in some cases, they 360 had also explicitly consented to take part in DAT implementation projects (10), which could also 361 introduce bias. Timing of DAT performance assessment relative to reference standard measures may 362 also have been an issue. There were fewer concerns about applicability with respect to participant 363 profiles, DATs used, or reference standards (Figure S1b). Details of the quality assessment criteria are 364 provided in Table S7.

365 **Publication bias.** There was visual asymmetry in the funnel plot displaying diagnostic odds 366 ratios and effective sample sizes, indicating possible publication bias (Figure S2). There were too few 367 studies to permit formal quantitative evaluation of publication bias. Additionally, the effective sample

sizes do not account for within-individual clustering and are therefore overestimated for these articles
(33,37). Several could not be included because of insufficient data to estimate the diagnostic odds
ratios.

371 GRADE Results. The findings suggested moderate certainty of evidence for the sensitivity of 372 ingestible sensors, because of consistent and precise results, a low risk of bias, but an inability to assess 373 publication bias. The certainty of evidence was very low for medication sleeves with phone calls because 374 of substantial risks of bias, and substantial variation in sensitivity and specificity across articles. Similarly, 375 the certainty of evidence was very low for digital pillboxes. More details on the quality of evidence for 376 each DAT can be found in Table S8-10 and Figure S3. A GRADE assessment was not conducted for the 377 DATs using AI and reader software since these involved only one report each.

378 **DISCUSSION** (1,126 words, including conclusion)

379 Available evidence addressing the performance of DATs for measuring TB medication adherence 380 is limited in scope and quality. Among 13 reports which considered five types of DATs, there was 381 substantial variation in reference standards, definitions of adherence, and adherence classifications, 382 which made it difficult to compare and summarize results. Ingestible sensors showed relatively high 383 sensitivity under experimental conditions in high-income countries, but this technology may be too 384 expensive to scale up in the near future and will face substantial barriers to real world implementation 385 in LMICs with high TB incidence. In general, however, studies of DAT implementation in real world 386 settings (medication sleeves with phone calls, digital pillboxes) found suboptimal performance of these 387 technologies for measuring medication adherence. These findings are concordant with a previous 388 review that assessed the accuracy of electronic monitoring in devices in antiretroviral medication 389 adherence.(39)

390 To understand the suboptimal performance of DATs during real world implementation, it is 391 important to consider that this reflects the ways in which people undergoing TB treatment do or do not

392 engage with the technology. Engagement may be influenced by technical attributes of the DAT and the 393 motivations, beliefs, social context, and structural barriers faced by people with TB. Suboptimal 394 engagement with DATs—which may result in under-reporting of true medication adherence (i.e., 395 reduced sensitivity, reduced NPV)—can be influenced by limited access to mobile networks and 396 technology, shared cellphone use among multiple household members, and inadequate education on 397 the purpose and appropriate use of the DAT.(40–43) With substantial under-reporting of medication 398 adherence, healthcare providers may have difficulty identifying people who are truly experiencing 399 nonadherence, be unable to routinely reach out to all people with reported nonadherence (e.g., via 400 phone calls or home visits) (44), and may begin to ignore digital adherence data due to its limited 401 performance (42,44). 402 Conversely, over-reporting of adherence (i.e., reduced specificity, reduced PPVs)—in which 403 people with TB or healthcare providers may report adherence via phone call or pillbox opening despite 404 medication doses not actually ingested—may result from the desire by people with TB to conceal 405 nonadherence or by the desire of healthcare providers to report optimal TB outcomes.(45) Over-406 reporting of adherence may be more concerning, as healthcare providers and health systems may miss 407 early identification of people who need intensified or personalized support to improve adherence and 408 ensure optimal treatment outcomes. 409 Several challenges limited our interpretation of DAT performance. The certainty around 410 evidence of performance for DATs under programmatic conditions was very limited. Additionally, the 411 use of different pill taking thresholds to define adherence, and of different windows for dose recording 412 vs. urine testing, adds substantial complexity and makes it even more difficult to summarize the 413 available evidence. One study evaluated digital pillboxes in an inpatient setting, which differs

414 substantially from the settings where DATs would most likely be used and limits the relevance of the

415 resulting data. Another used a method for documenting the presence or absence of rifampin in urine,

416 which was not used in other studies, highlighting the importance of consistent reference standards.
417 More generally, the use of urine tests as reference standards can be problematic, given known gaps in
418 their performance. This includes suboptimal sensitivity (based on witnessed pill ingestion) for doses
419 ingested over 24 hours before testing (46), and suboptimal specificity for doses ingested over 72 hours
420 before testing.(12,47) Similarly, while pill count is a standard method for determining adherence, pills
421 missing during routine pill counts may not have been ingested.

422 **Strengths and Limitations.** To our knowledge, this is the first systematic review focusing 423 specifically on the performance of DATs for measuring TB medication adherence. We used a wide-424 ranging, pre-specified search strategy across multiple databases, without language restriction and with 425 the potential inclusion of suitable reports from grey literature, including preprints. Our search was 426 developed and conducted by an experienced health sciences librarian. Selection of reports and data 427 extraction were performed rigorously, by two independent reviewers at every step. Whenever possible, 428 we used primary data from each report to estimate any relevant performance parameters that the 429 authors had not reported. We also assessed the quality and robustness of the available evidence. 430 For logistical reasons, we could not systematically search for and retrieve abstracts other than 431 those presented at the conferences of the International Union Against Tuberculosis and Lung Disease, 432 which is the major venue for public health-oriented TB research. Some reports did not include sufficient 433 data to permit estimation of all performance parameters of interest. Additionally, there may be an 434 underestimation of the variance in instances where clustering was not considered (i.e., for repeated 435 measurements per individual). We did not identify any reports evaluating the performance of doses 436 observed by video against urine tests or pill counts, although video-supported treatment has been used 437 increasingly in high-income countries.(48–50) Finally, given the heterogeneity of study methods, 438 technologies, and results, we did not formally pool or meta-analyze their data. We have instead

summarized the key results from each study in tabular and/or graphic format, and provided an overview
of the results for each key technology.

441 Changes to the protocol. Changes were made to our pre-registered protocol in PROSPERO as 442 follows. We additionally searched Europe PMC for pre-print articles relevant to our review. We did not 443 anticipate the use of DOT, or provider-based DAT decisions as reference standards for quantifying DAT 444 performance, and therefore added them as possible comparators. We also did not anticipate articles 445 that used the DAT as the reference standard. For those reports, we back-calculated the published results 446 to provide us with the performance of the DAT as the index test.

447 **CONCLUSIONS**

448 Accurate dose reporting is fundamental to the use of digital technologies to aid treatment 449 adherence. Their use as alternatives to traditional direct observation is predicated on the concept that 450 providers and health programs can provide additional support to people who appear to be facing 451 challenges in this regard. Hence suboptimal performance of dose reports from DATs can potentially 452 compromise their effectiveness, as well as program efficiency. If the DAT fails to capture significant non-453 adherence, this leads to missed opportunities for intervention, and potentially even poorer treatment 454 outcomes. On the other hand, if support and supervision are intensified for people wrongly labeled as 455 poorly adherent by the DAT, this is a waste of limited program resources. The future evidence base will 456 be strengthened by more consistent definitions and cutoffs for adherence, and by more consistent use 457 of one or more reference standards—e.g. validated methods for pill counts, standardized timing and 458 technique for urine tests. Future research should also address the interplay of specific technology, 459 setting, user characteristics, and user engagement with DAT performance. Additional studies examining 460 the performance of asynchronous video observation will also be important, as will further investigation 461 of digital technologies to support newer treatment regimens for TB disease and infection.

462 **FIGURE LEGENDS**

463 Figure 1: PRISMA 2020 Flow Diagram of studies identified and included. Studies were identified via 464 databases and registries, and via other methods related to the performance of DATs for measuring TB 465 medication adherence. Other methods included searching the references and citations of included 466 studies identified from databases and registries, searching the references and citations of the studies 467 included our linked systematic reviews, and searching the abstracts of the Union World Conference of 468 Lung Health and Tuberculosis from 2004 to 2022. Database and registry searches were conducted on 469 April 28, 2023 from January 1, 2000 to April 28, 2023. 470 Figure 2: Forest plot of the sensitivity and specificity of a) ingestible sensors, b) Medication sleeves 471 with phone calls ["99DOTS"], and c) Digital pillboxes. a) DOT was used as the reference standard. 472 Sensitivity was calculated using the reported positive detection accuracy of each study (# of ingestible 473 sensors detected/# of ingestible sensors ingested). Specificity was not estimable due to the lack of false 474 positives and true negatives. Browne et al. (30) confidence intervals account for within-individual 475 clustering. b) INH urine test was used as the reference standard. DAT adherence was recorded using 476 "patient-reported doses", wherein dose reporting relies only on calls made by the person receiving 477 treatment. c) Pill count was used as the reference standard. Results are depicted for persons with 478 tuberculosis disease or infection. Bionghi et al. (33) was an inpatient cohort. Scott et al. (32) used a 479 cohort of persons with TB infection (TBI). In Ruslami et al. (36) and van den Boogaard et al. (35), the 480 digital pillbox was used as the reference standard. Number of true positives, false positives, false 481 negatives, and true negatives were back-calculated from the article's primary data on pill count 482 sensitivity and specificity, and number of events.

483

484

485 **DECLARATIONS**

- 486 **Ethics approval and consent to participate:** Not applicable
- 487 **Consent for publication:** Not applicable
- 488 Availability of data and materials: The data and materials supporting the conclusions of this article that
- 489 are not already shared in the manuscript and appendix are available at
- 490 https://borealisdata.ca/dataverse/mcgill
- 491 **Competing interests:** Dr. Kevin Schwartzman reports research funding from the Canadian Institutes of
- 492 Health Research. He has also served as chair of the Data Safety and Monitoring Board for a COVID-19
- 493 therapeutic investigated by Laurent Pharmaceutical.
- 494 **Funding:** This review was supported by a grant from the Bill and Melinda Gates Foundation (grant INV-
- 495 038215). The funder had no role in the execution or reporting of this study, in manuscript preparation,
- 496 or in the decision to publish.
- 497 **Authors' contributions:** All authors contributed to the design of the research and approved the final
- 498 manuscript. MZ contributed to screening, data extraction and analysis, and drafted the manuscript. MS
- 499 contributed to the database search, screening, data extraction, and provided systematic review
- 500 expertise for the manuscript. CK contributed to screening and data extraction. GG contributed to the
- 501 database search. CC, SB, and NF contributed to screening. KF, RS, and KS provided support in all steps of
- 502 executing the review and revised the manuscript.
- 503 Acknowledgements: Part of this work was presented in abstract and poster format at the 2023 North
- 504 America Region Conference of the International Union of Tuberculosis and Lung Disease on Tuberculosis

505 (51).

- 506
- 507
- 508
- 509

510		
511 512	REFE	RENCES
513 514	1.	Global Tuberculosis Report [Internet]. World Health Organization. 2021 [cited 2022 Jul 27].
515		Available from: https://www.who.int/publications/i/item/9789240037021
516	2.	Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital
517		adherence technologies for the management of tuberculosis therapy: mapping the landscape
518		and research priorities. BMJ Glob Heal. 2018;3(5):e001018.
519	3.	Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis
520		infection in a clinical population in New York City. Int J Infect Dis [Internet]. 2010;14(4):e292–7.
521		Available from: https://www.sciencedirect.com/science/article/pii/S1201971209002124
522	4.	Chung SJ, Lee H, Koo GW, Min JH, Yeo Y, Park DW, et al. Adherence to nine-month isoniazid for
523		latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital. Sci
524		Rep. 2020 Apr;10(1):6462.
525	5.	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment,
526		Tuberculosis care and support [Internet]. WHO Press. 2022. 98 p. Available from:
527		https://tbksp.org/en/node/1898
528	6.	Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst
529		Rev. 2015;2015(5).
530	7.	Sagbakken M, Frich JC, Bjune GA, Porter JDH. Ethical aspects of directly observed treatment for
531		tuberculosis: a cross-cultural comparison. BMC Med Ethics [Internet]. 2013;14(1):25. Available
532		from: https://doi.org/10.1186/1472-6939-14-25
533	8.	Yellappa V, Lefèvre P, Battaglioli T, Narayanan D, Van der Stuyft P. Coping with tuberculosis and
534		directly observed treatment: a qualitative study among patients from South India. BMC Health
535		Serv Res [Internet]. 2016;16(1):283. Available from: https://doi.org/10.1186/s12913-016-1545-9

536	9.	Thomas BE, Kumar JV, Chiranjeevi M, Shah D, Khandewale A, Thiruvengadam K, et al. Evaluation
537		of the Accuracy of 99DOTS, a Novel Cellphone-based Strategy for Monitoring Adherence to
538		Tuberculosis Medications: Comparison of DigitalAdherence Data with Urine Isoniazid Testing. Clin
539		Infect Dis. 2020;71(9):E513–6.
540	10.	Efo E, Onjare B, Shilugu L, Levy J. Acceptability, feasibility and accuracy of 99DOTS adherence
541		technology in mining region of Tanzania. 2021 IST-Africa Conf IST-Africa 2021. 2021;(5):1–12.
542	11.	Alacapa J, Morales M, Levy J, Powers R, Villaneuva A. Evaluation of the accuracy of 99DOTS digital
543		adherence technology for tuberculosis in Metro Manila, the Philippines. World Conf Lung Heal Int
544		Union Against Tuberc Lung Dis (The Union). 2020;24.
545	12.	Subbaraman R, Thomas BE, Kumar JV, Lubeck-Schricker M, Khandewale A, Thies W, et al.
546		Measuring tuberculosis medication adherence: a comparison of multiple approaches in relation
547		to urine isoniazid metabolite testing within a cohort study in India. Open Forum Infect Dis.
548		2021;1–8.
549	13.	Wang N, Shewade HD, Thekkur P, Zhang H, Yuan Y, Wang X, et al. Do electronic medication
550		monitors improve tuberculosis treatment outcomes? Programmatic experience from China. PLoS
551		One [Internet]. 2020;15(11 November):1–11. Available from:
552		http://dx.doi.org/10.1371/journal.pone.0242112
553	14.	Chen AZ, Kumar R, Baria RK, Shridhar PK, Subbaraman R, Thies W. Impact of the 99DOTS digital
554		adherence technology on tuberculosis treatment outcomes in North India: a pre-post study. BMC
555		Infect Dis [Internet]. 2023;23(1):1–10. Available from: https://doi.org/10.1186/s12879-023-
556		08418-2
557	15.	Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The
558		impact of digital health technologies on tuberculosis treatment: a systematic review. Abubakar I,

Alipanah N, Bastos M, Boccia D, Chin D, Cohen T, et al., editors. Eur Respir J [Internet]. 2018;51.

560 Available from: https://erj.ersjournals.com/content/51/1/1701596

- 561 16. Nglazi MD, Bekker LG, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for
- 562 promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis. 2013
- 563 Dec;13:566.
- 564 17. Ridho A, Alfian SD, van Boven JFM, Levita J, Yalcin EA, Le L, et al. Digital Health Technologies to
- 565 Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis:
- 566 Systematic Review of Randomized Controlled Trials. J Med Internet Res. 2022 Feb;24(2):e33062.
- 567 18. Schwartzman K, Mappin-Kasirer B, Mohamed MS, Zary M, Kafie C, Subbaraman R, et al.
- 568 PROSPERO 2022 CRD42022313526: The Accuracy of Dose Reports generated by Digital
- 569 Adherence Technologies for Persons treated for Tuberculosis Disease or Infection: A Systematic
- 570 Review and Meta-Analysis [Internet]. 2022. Available from:
- 571 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022313526
- 572 19. Rutjes AWS, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PMM. Case-control and two-gate

573 designs in diagnostic accuracy studies. Clin Chem. 2005;51(8):1335–41.

- 574 20. EndNote v20.2.1 [Internet]. Clarivate; 2023. Available from: https://endnote.com/
- 575 21. Rayyan Al Powered Tool for Systematic Literature Reviews [Internet]. Rayyan; 2022. Available
 576 from: https://www.rayyan.ai/
- 577 22. Google Scholar [Internet]. 2023 [cited 2022 Aug 2]. Available from: https://scholar.google.com/
- 578 23. Review Manager (RevMan). The Cochrane Collaboration; 2020.
- 579 24. RStudio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, PBC; 2020.
- 580 25. Van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication bias in
- 581 meta-analyses of diagnostic test accuracy: A meta-epidemiological study. BMC Med Res
- 582 Methodol. 2014;14(1):1–11.
- 583 26. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A

- 584 Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med
- 585 [Internet]. 2011 Oct 18;155(8):529–36. Available from:
- 586 https://www.acpjournals.org/doi/abs/10.7326/0003-4819-155-8-201110180-00009
- 587 27. Schünemann H, Brożek J, Guyatt G, Oxman A. The GRADE Working Group. 2013 [cited 2023 Apr
- 588 14]. GRADE Handbook for grading quality of evidence and strength of recommendations.
- 589 Available from: https://gdt.gradepro.org/app/handbook/handbook.html#h.f7lc8w9c3nh8
- 590 28. McMaster University and Evidence Prime. GRADEpro GDT: GRADEpro Guideline Development
- 591 Tool [Internet]. 2022. Available from: gradepro.org
- 592 29. Google Translate [Internet]. 2023 [cited 2023 Aug 2]. Available from: https://translate.google.ca/
- 593 30. Browne SH, Umlauf A, Tucker AJ, Low J, Moser K, Garcia JG, et al. Wirelessly observed therapy
- 594 compared to directly observed therapy to confirm and support tuberculosis treatment

adherence: A randomized controlled trial. PLoS Med. 2019;16(10):1–19.

- 596 31. Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, et al. Feasibility of an Ingestible
- 597 Sensor-Based System for Monitoring Adherence to Tuberculosis Therapy. PLoS One. 2013;8(1):8–
- 598 12.
- 599 32. Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, et al. Using a medication event
- 600 monitoring system to evaluate self-report and pill count for determining treatment completion
- 601 with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023
- 602 Jun;129:107173.
- 603 33. Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico KR, Friedland G, et al. Pilot evaluation of a
- 604 second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in
- 605 drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infect Dis.
- 606 2018;18(1):1–9.
- 607 34. HUAN Shi-tong LIU Xiao-qiu, OU Xi-chao, JIANG Shi-wen, ZHAO Yan-lin, ZHANG Zhi-ying, ZHAN Si-


- 608 yan CR. Operational feasibility of medication monitors in monitoring treatment adherence
- among TB patients [Internet]. Vol. 34, Chinese Journal of Antituberculosis. p. 419–24. Available
- 610 from: http://www.zgflzz.cn
- 611 35. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of
- 612 treatment adherence and validation of alternative adherence measures in tuberculosis patients:
- 613 A pilot study. Bull World Health Organ. 2011;89(9):632–9.
- 614 36. Ruslami R, Van Crevel R, Van De Berge E, Alisjahbana B, Aarnoutse RE. A step-wise approach to
- 615 find a valid and feasible method to detect non-adherence to tuberculosis drugs. Southeast Asian
- 616 J Trop Med Public Health. 2008;39(6):1083–7.
- 617 37. Sekandi JN, Shi W, Zhu R, Kaggwa P, Mwebaze E, Li S. Application of Artificial Intelligence to the
- 618 Monitoring of Medication Adherence for Tuberculosis Treatment in Africa: Algorithm
- 619 Development and Validation. JMIR AI [Internet]. 2023;2:e40167. Available from:
- 620 https://ai.jmir.org/2023/1/e40167
- 621 38. Goodwin K, Liao Z, Iribarren S. Assessing and refining image analysis software to automate
- 622 reading of objective home-based TB adherence tests. World Conf Lung Heal Int Union Against
- 623 Tuberc Lung Dis (The Union). 2022;26.
- 624 39. Smith R, Villanueva G, Probyn K, Sguassero Y, Ford N, Orrell C, et al. Accuracy of measures for
- 625 antiretroviral adherence in people living with HIV. Cochrane Database Syst Rev. 2022;2022(7).
- 626 40. Thomas BE, Kumar JV, Periyasamy M, Khandewale AS, Hephzibah Mercy J, Raj EM, et al.
- 627 Acceptability of the Medication Event Reminder Monitor for Promoting Adherence to Multidrug-
- 628 Resistant Tuberculosis Therapy in Two Indian Cities: Qualitative Study of Patients and Health Care
- 629 Providers. J Med Internet Res [Internet]. 2021;23(6):e23294. Available from:
- 630 https://www.jmir.org/2021/6/e23294
- 631 41. Thomas BE, Kumar JV, Onongaya C, Bhatt SN, Galivanche A, Periyasamy M, et al. Explaining

- 632 Differences in the Acceptability of 99DOTS, a Cell Phone–Based Strategy for Monitoring
- 633 Adherence to Tuberculosis Medications: Qualitative Study of Patients and Health Care Providers.
- 534 JMIR Mhealth Uhealth [Internet]. 2020;8(7):e16634. Available from:
- 635 http://mhealth.jmir.org/2020/7/e16634/
- 636 42. Bahukudumbi S, Chilala C, Mohamed M, Zary M, Kafie C, Foster N, et al. Contextual factors
- 637 impacting the implementation of TB digital adherence technologies: A scoping review. In: World
- 638 Conference on Lung Health 2023 of the International Union Against Tuberculosis and Lung
- 639 Disease (The Union) [Internet]. Paris, France; 2023. p. S124-125. Available from:
- 640 https://conf2023.theunion.org/wp-content/uploads/2023/12/UNION2023_Abstracts.pdf
- 641 43. Chilala C, Bahukudumbi S, Foster N, Mohamed M, Zary M, Kafie C, et al. Implementation
- 642 outcomes of TB digital adherence technologies: A scoping review using the RE-AIM Framework.
- 643 In: World Conference on Lung Health 2023 of the International Union Against Tuberculosis and
- 644 Lung Disease (The Union) [Internet]. Paris, France; 2023. p. S97–8. Available from:
- 645 https://conf2023.theunion.org/wp-content/uploads/2023/12/UNION2023_Abstracts.pdf
- 646 44. Thekkur P, Kumar AM V, Chinnakali P, Selvaraju S, Bairy R, Singh AR, et al. Outcomes and
- 647 implementation challenges of using daily treatment regimens with an innovative adherence
- 648 support tool among HIV-infected tuberculosis patients in Karnataka, India: a mixed-methods
- 649 study. Glob Health Action [Internet]. 2019 Jan 1;12(1):1568826. Available from:
- 650 https://doi.org/10.1080/16549716.2019.1568826
- 45. Thomas B, Kumar V, Chiranjeevi M, Ramachandran G, Murugesan P, Khandewale A, et al.
- 652 Understanding challenges TB patients face in using digital adherence technologies. In: 50th
- 653 World Conference on Lung Health of the International Union Against Tuberculosis and Lung
- Disease (The Union). Hyderabad, India; 2019. p. S236.
- 46. Soobratty MR, Whitfield R, Subramaniam K, Grove G, Carver A, O'Donovan G V, et al.

- 656 Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis. Eur
- 657 Respir J [Internet]. 2014 May 1;43(5):1519 LP 1522. Available from:
- 658 http://erj.ersjournals.com/content/43/5/1519.abstract
- 47. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant AD. Evaluation of the Arkansas
- 660 method of urine testing for isoniazid in South Africa. Int J Tuberc lung Dis Off J Int Union against
- 661 Tuberc Lung Dis. 2007 Nov;11(11):1232–6.
- 662 48. Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of
- tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc lung

Dis Off J Int Union against Tuberc Lung Dis. 2016 May;20(5):588–93.

- 49. Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using Video Technology
- to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month
- Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res. 2018 Nov;20(11):e287.
- 668 50. Beeler Asay GR, Lam CK, Stewart B, Mangan JM, Romo L, Marks SM, et al. Cost of Tuberculosis
- 669 Therapy Directly Observed on Video for Health Departments and Patients in New York City; San
- 670 Francisco, California; and Rhode Island (2017-2018). Am J Public Health. 2020 Nov;110(11):1696–
- 671 **703**.
- 51. Zary M, Mohamed MS, Kafie C, Chilala Cl, Bahukudumbi S, Fielding K, et al. The Accuracy of Dose
- 673 Reports Generated by Digital Adherence Technologies for Persons Treated for Tuberculosis
- Disease or Infection: A Systematic Review. In: 27th Annual Conference of the Union-North
- 675 America Region Conference on Tuberculosis [Internet]. 2023. p. 18. Available from:
- 676 https://bclung.ca/sites/default/files/2023 NAR Conference Abstracts.pdf



dentification

ncluded

a) Ingestible sensors

Study	ТР	FP	FN	ΤN	Reference Standard D	OAT Adherence Classification	Sensitivity (95% CI)	Specificity (95% CI)
Belknap et al. 2013	1026	0	54	0	DOT	1 detected dose	0.95 [0.94, 0.96]	Not estimable
Browne et al. 2019	680	0	5	0	DOT	1 detected dose	0.99 [0.98, 1.00]	Not estimable

b) Medication sleeves with phone calls ["99DOTS"]

Study	ТР	FP	FN	ΤN	Reference Standard	DAT Adherence Classification	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI) Specificity (95% CI)
Alacapa et al. 2020 (Abstract)	95	2	6	0	INH Urine Test	1 reported dose in prior 48h	0.94 [0.88, 0.98]	0.00 [0.00, 0.84]	-
Efo et al. 2021	138	7	41	11	INH Urine Test	1 reported dose in prior 48h	0.77 [0.70, 0.83]	0.61 [0.36, 0.83]	• — •
Thomas et al. 2020	368	28	157	44	INH Urine Test	1 reported dose in prior 6-48h	0.70 [0.66, 0.74]	0.61 [0.49, 0.72]	
									0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1

Sensitivity (95% Cl) Specificity (95% Cl)

c) Digital pillboxes

Study	ТР	FP	FN	ΤN	Reference Standard	DAT Adherence Classification	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% Cl) Specificity (95% Cl)
(TBI) Scott et al. 2023	497	0	40	128	Pill Count	≥ 11/12 doses recorded	0.93 [0.90, 0.95]	1.00 [0.97, 1.00]	
Bionghi et al. 2018	480	0	6	3	Pill Count	1 dose recorded	0.99 [0.97, 1.00]	1.00 [0.29, 1.00]	· · · · · · · · · · · · · · · · · · ·
Ruslami et al. 2008	15	2	5	8	Pill Count	100% doses recorded	0.75 [0.51, 0.91]	0.80 [0.44, 0.97]	_
van den Boogaard et al. 2011	6	4	18	9	Pill Count	100% doses recorded	0.25 [0.10, 0.47]	0.69 [0.39, 0.91]	